View Older Stories View More Recent Stories

Oct 20, 2020 04:05PM Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
Oct 2, 2020 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2020 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 15, 2020 08:30AM Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress
Sep 15, 2020 08:30AM Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress
Sep 11, 2020 08:32AM Prothena Corp. (PRTA) Reports Data from Phase 2 PASADENA Study of Prasinezumab Demonstrates Slowing Progression on Measures of Parkinson’s Disease
Sep 11, 2020 08:30AM Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
Sep 11, 2020 08:30AM Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
Sep 8, 2020 04:05PM Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15
Sep 8, 2020 04:05PM Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15
Sep 3, 2020 04:05PM Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders
Sep 3, 2020 04:05PM Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders
Sep 2, 2020 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2020 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 6, 2020 04:05PM Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update
Aug 6, 2020 04:05PM Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update
Aug 5, 2020 04:05PM Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders
Aug 5, 2020 04:05PM Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders
Jul 30, 2020 04:05PM Prothena to Report Second Quarter 2020 Financial Results on August 6
Jul 30, 2020 04:05PM Prothena to Report Second Quarter 2020 Financial Results on August 6
May 27, 2020 04:05PM Prothena to Present at the Jefferies Virtual Healthcare Conference on June 3
May 27, 2020 04:05PM Prothena to Present at the Jefferies Virtual Healthcare Conference on June 3
May 6, 2020 04:05PM Prothena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance
May 6, 2020 04:05PM Prothena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance
Apr 29, 2020 04:05PM Prothena to Report First Quarter 2020 Financial Results on May 6
Apr 29, 2020 04:05PM Prothena to Report First Quarter 2020 Financial Results on May 6
Apr 24, 2020 04:30PM Prothena Provides Additional Information Regarding Upcoming Annual General Meeting of Shareholders in Response to COVID-19
Apr 24, 2020 04:30PM Prothena Provides Additional Information Regarding Upcoming Annual General Meeting of Shareholders in Response to COVID-19
Apr 22, 2020 09:17AM Prothena Corp. (PRTA) Phase 2 PASADENA Study of Prasinezumab in Parkinson’s Disease Did Not Meet Primary Objective but Showed Signals of Efficacy
Apr 22, 2020 09:15AM Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease
Apr 22, 2020 09:15AM Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease
Apr 3, 2020 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Apr 3, 2020 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 31, 2020 04:05PM Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease to be Presented at AAT-AD/PD
Mar 31, 2020 04:05PM Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease to be Presented at AAT-AD/PD
Mar 3, 2020 04:05PM Prothena Announces Appointment of Brandon Smith as Chief Business Officer
Mar 3, 2020 04:05PM Prothena Announces Appointment of Brandon Smith as Chief Business Officer
Feb 12, 2020 04:05PM Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update
Feb 12, 2020 04:05PM Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update
Dec 5, 2019 04:05PM Prothena Announces Appointment of Oleg Nodelman to its Board of Directors
Dec 5, 2019 04:05PM Prothena Announces Appointment of Oleg Nodelman to its Board of Directors
Nov 5, 2019 04:05PM Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update
Nov 5, 2019 04:05PM Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update
Oct 29, 2019 04:05PM Prothena to Report Third Quarter 2019 Financial Results on November 5
Oct 29, 2019 04:05PM Prothena to Report Third Quarter 2019 Financial Results on November 5
Aug 6, 2019 04:05PM Prothena Reports Second Quarter 2019 Financial Results and Provides R&D Update
Aug 6, 2019 04:05PM Prothena Reports Second Quarter 2019 Financial Results and Provides R&D Update
Jul 30, 2019 04:05PM Prothena to Report Second Quarter 2019 Financial Results on August 6
Jul 30, 2019 04:05PM Prothena to Report Second Quarter 2019 Financial Results on August 6
Jul 1, 2019 04:08PM Prothena Corp. (PRTA) Names Paula K. Cobb to Board
View More Recent Stories View Older Stories